Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Pfizer Rheumatoid Arthritis Drug Meets Study Goals

By Pharmaceutical Processing | June 11, 2009

NEW YORK (AP) — Pfizer Inc. said Thursday its experimental oral treatment for rheumatoid arthritis has met key goals in two midstage studies by improving tender and swollen joints. In a study involving 384 participants, various doses of the CP-690,550 drug candidate prompted responses in 49 percent to 75 percent of patients, compared with 28.8 percent of patients taking placebo. Another study involving 136 patients yielded similar results. “This compound could represent a promising advance in rheumatoid arthritis treatment for patients who need an alternative to currently available therapies,” said Dr. Michael Berelowitz, Pfizer’s senior vice president of clinical development and medical affairs for the specialty care unit. While the drug is still years away from market, it could eventually become a key competitor to several blockbuster treatments. A key advantage would be that it is taken orally, instead of injected like current treatments such as Abbott Laboratories’ Humira, Johnson & Johnson’s Remicade, and Wyeth and Amgen Inc.’s Enbrel. Enbrel topped all others in 2008 with sales of $3.4 billion. Belgian drug developer UCB recently gained approval for its injectable treatment Cimzia. It has already been approved to treat gastrointestinal Crohn’s disease. The Pfizer results were presented at the 10th annual congress of the European League Against Rheumatism in Copenhagen. The main results are taken from a 12-week analysis of a six-month study and confirm prior positive midstage study data, the company said. Pfizer is also currently conducting a late-stage clinical trial on the drug candidate.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE